4.1 The objective of this document is to provide guidance in the production, characterization, testing, and standardization of: (1) polymerizable collagen starting materials; and (2) collagen polymeric materials produced with polymerizable collagen formulations, used for surgical implants, substrates for TEMPs, vehicles for therapeutic cells and molecules, and 3D in-vitro tissue systems for basic research, drug development, and toxicity testing. This guide can be used as an aid in the selection, characterization, and standardization of the appropriate polymerizable collagen starting formulations as well as collagen polymeric materials prepared from polymerizable collagens for a specific use. Not all tests or parameters are applicable to all uses of collagen and users are expected to select and justify a subset of the tests for characterization purposes.4.2 This guide can be used by the following types of users:4.2.1 Manufacturers of polymerizable collagens and collagen polymeric materials who wish to set specifications for their products or provide characterization data for customers or users. They may also use the terminology and characterization sections to specify and differentiate the properties of polymerizable collagens and collagen polymeric materials.4.2.2 Producers of collagen polymeric materials that use polymerizable collagen as starting materials. Producers may use this guide to evaluate and characterize multiple sources of polymerizable collagen. They may also use this guide to assist with evaluation and comparison of single or multiple sources of polymerizable collagen and collagen polymeric materials.4.2.3 Researchers may use this guide as a reference for properties and test methods that can be used to reproducibly evaluate polymerizable collagens and collagen polymeric materials.4.3 The collagen covered by this guide may be used in a broad range of applications, forms, or medical products, for example (but not limited to) wound and hemostatic dressings, surgical implants or injectables (including in-situ forming), hybrid medical devices, TEMPs, injectable (including in-situ forming) or implantable delivery vehicles for therapeutic cells, molecules, and drugs, and 3D in-vitro tissue systems or models for basic research, drug development, and toxicity testing. The practical application of polymerizable collagens and collagen polymeric materials should be based, among other factors, on biocompatibility, application-specific performance measures, as well as chemical, physical, and biological test data. Recommendations in this guide should not be interpreted as a guarantee of success for any specific research or medical application.4.4 The following general areas should be considered when determining if the collagen supplied satisfies requirements for use in the above mentioned medical and research applications: source of polymerizable collagen, impurities profile, and comprehensive chemical, physical, and biological characterization and testing.4.5 The following documents or other relevant guidance documents from appropriate regulatory bodies relating to the production, regulation, and regulatory approval of devices, biologics, drugs, and combination products should be considered when determining if the collagen supplied satisfies requirements for use in medical and research products, including TEMPs, therapeutic delivery vehicles, and 3D in-vitro tissue systems:FDA CFR:21 CFR 3: Product Jurisdiction:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/    CFRSearch.cfm?CFRPart=321 CFR 58: Good Laboratory Practice for Nonclinical Laboratory Studies:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/    CFRSearch.cfm?CFRPart=58 FDA/CDRH CFR and Guidances:21 CFR Part 803: Medical Device Reporting:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/    CFRSearch.cfm?CFRPart=80321 CFR 812: Investigational Device Exemptions:    http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/    CFRSearch.cfm?CFRPart=81221 CFR 814: Premarket Approval of Medical Devices:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/    CFRSearch.cfm?CFRPart=81421 CFR 820: Quality System Regulation:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/    CFRSearch.cfm?CFRPart=820Design Control Guidance for Medical Device Manufacturers:   http://www.fda.gov/cdrh/comp/designgd.pdfPreproduction Quality Assurance Planning Recommendations for Medical Device Manufacturers (FDA 90-4236):   http://www.fda.gov/cdrh/manual/appende.htmlThe Review and Inspection of Premarket Approval Applications under the Bioresearch Monitoring Program—Draft Guidance for Industry and FDA Staff:   http://www.fda.gov/cdrh/comp/guidance/1602.pdf FDA/CDRH Search Engines:CDRH Guidance Search Engine:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfggp/   search.cfmCDRH Premarket Approval (PMA) Search Engine:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/   pma.cfmCDRH 510(k) Search Engine:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/   pmn.cfmCDRH Recognized STANDARDS Search Engine:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/   search.cfm FDA/CBER CFR and Guidances:21 CFR 312: Investigational New Drug Application:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/    CFRSearch.cfm?CFRPart=31221 CFR 314: Applications for FDA Approval to Market a New Drug:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/    CFRSearch.cfm?CFRPart=3121 CFR 610: General Biological Products Standards:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/    CFRSearch.cfm?CFRPart=61021 CFR 1271: Human Cells, Tissues and Cellular and Tissue-Based Products:   http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/    CFRSearch.cfm?CFRPart=1271Cellular & Gene Therapy Guidances and Other Publications:   http://www.fda.gov/cber/genetherapy/gtpubs.htmHuman Tissue Guidances and Other Publications:   http://www.fda.gov/cber/tissue/docs.htmCBER Product Approval Information:   http://www.fda.gov/cber/efoi/approve.htm21 CFR 600, 601 BLA Regulations:   http://www.access.gpo.gov/nara/cfr/waisidx_07/21cfrv7_07.html21 CFR 210, 211 GMP Regulations:   http://www.access.gpo.gov/nara/cfr/waisidx_07/21cfr210_07.html1.1 This guide is intended to provide characteristics, properties, test methods, and standardization approaches for evaluation and identification of specific polymerizable collagen formulations and collagen polymeric materials produced with these formulations.1.2 This guide focuses on characterization of purified polymerizable forms of type I collagen, which is the most abundant collagen in mammalian connective tissues and organs, including skin, bone, tendon, and blood vessels. Polymerizable type I collagen may be derived from a variety of sources including, but not limited to, animal or cadaveric tissues, cell culture, recombinant cell culture, and chemical synthesis.1.2.1 This guide covers evaluation of polymerizable collagens and collagen polymeric materials prepared from polymerizable collagens for use as a starting material for wound and hemostatic dressings, surgical implants, substrates for tissue-engineered medical products (TEMPs), delivery vehicles for therapeutic cells or molecules, and 3D in-vitro tissue systems for basic research, diagnostics, drug development, and toxicity testing. Most collagen products on the market today are regulated as devices since their primary intended purpose is not achieved through chemical action within or on the body. However, a medical product comprising polymerizable collagens or collagen polymeric materials may be regulated as a device, biologic, drug, or combination product depending on its intended use and primary mode of action.1.2.2 Polymerizable collagen or collagen self-assembly implies that the collagen composition exhibits spontaneous macromolecular assembly from its components without the addition of exogenous factors such as cross-linking agents. Polymerizable collagens may include but are not limited to: (1) tissue-derived monomeric collagens, including tropocollagen or atelocollagen, and oligomeric collagens; (2) collagen proteins and peptides produced through in vitro cell culture, with or without using recombinant technology; and (3) chemically synthesized collagen mimetic peptides. It should be noted that the format of collagen polymeric material products also will vary and may include injectable solutions that polymerize in situ as well as preformed sheets, particles, spheres, fibers, sponges, matrices/gels, coatings, films, and other forms.1.2.3 This guide may serve as a template for characterization and standardization of type I fibrillar collagen or other collagen types that demonstrate polymerization or self-assembly.1.3 This guide does not provide a significant basis for assessing the biological safety (biocompatibility) of polymerizable collagens and collagen polymeric materials. While the ability of collagen polymeric materials to guide cellular responses through provision of cellular adhesion and proteolytic domains as well as physical constraints (for example, structural, cell-matrix traction force) has been well documented through extensive clinical and basic research studies (1-5),2 users are directed to the ISO 10993 series for evaluating biological risks of medical devices. The biocompatibility and appropriateness of use for a specific application is the responsibility of the product manufacturer.1.4 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.1.5 The following precautionary caveat pertains only to the test method portion, Sections 6 and 7, of this guide: This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.1.6 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

定价： 646元 / 折扣价： 550 元 加购物车

5.1 A large number of industrial processes involve transfer and feeding of bulk solids, and the ability of such materials to flow in a controlled manner during these operations is critical to product quality.5.2 Direct shear cells are among the most important methods for measuring the flow properties of bulk solids in industrial applications for bulk solids handling.5.3 Direct shear cells have many advantages over simpler methods of measuring bulk solids flow properties, but their operation is more complex and the procedures for their use must be carefully controlled to produce accurate and reproducible data.5.4 The three most popular direct shear cell types are: Translational (D6128), Annular (D6773), and Rotational (D6682 and D7891).5.5 From shear cell data, a wide variety of parameters can be obtained, including the yield locus representing the shear stress to normal stress relationship at incipient flow, angle of internal friction, unconfined yield strength, cohesion, and a variety of related parameters such as the flow function.5.6 In addition, these three direct shear cells can be set up with wall coupons to measure wall friction.5.7 When the shear cell data are combined with unconfined yield strength, wall friction data, and bulk density data, they can be used for bin and hopper evaluation and design.1.1 This guide covers theory and principles for obtaining reliable and accurate bulk solids flow data using a direct shear cell. It includes characteristics and limitations of the three most popular direct shear cell types: Translational (D6128), Annular (D6773), and Rotational (D6682 and D7891).1.2 Units—The values stated in SI units are to be regarded as standard. No other units of measure are included in this standard.1.3 This guide offers an organized collection of information or a series of options and does not recommend a specific course of action. This document cannot replace education or experience and should be used in conjunction with professional judgment. Not all aspects of this guide may be applicable in all circumstances. This ASTM standard is not intended to represent or replace the standard of care by which the adequacy of a given professional service must be judged, nor should this document be applied without consideration of a project’s many unique aspects. The word “Standard” in the title of this document means only that the document has been approved through the ASTM consensus process.1.4 This guide offers an organized collection of information or a series of options and does not recommend a specific course of action. This document cannot replace education or experience and should be used in conjunction with professional judgment. Not all aspects of this guide may be applicable in all circumstances. This ASTM standard is not intended to represent or replace the standard of care by which the adequacy of a given professional service must be judged, nor should this document be applied without consideration of a project’s many unique aspects. The word “Standard” in the title of this document means only that the document has been approved through the ASTM consensus process.1.5 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.1.6 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

定价： 590元 / 折扣价： 502 元 加购物车

3.1 The electrical sensing zone method for cell counting is used in tissue culture, government research, and hospital, biomedical, and pharmaceutical laboratories for counting and sizing cells. The method may be applicable to a wide range of cells sizes and cell types, with appropriate validation (10).3.2 The electrical sensing zone methodology was introduced in the mid-1950s (9). Since this time, there have been substantial improvements which have enhanced the operator's ease of use. Among these are the elimination of the mercury manometer, reduced size, greater automation, and availability of comprehensive statistical computer programs.3.3 This instrumentation offers a rapid result as contrasted to the manual counting of cells using the hemocytometer standard counting chamber. The counting chamber is known to have an error of 10 to 30 %, as well as being time-consuming (11). In addition, when counting and sizing porcine hepatocytes, Stegemann et al concluded that the automated, electrical sensing zone method provided greater accuracy, precision, and speed, for both counts and size, compared to the conventional microscopic or the cell mass-based method (7).1.1 This test method, provided the limitations are understood, covers a procedure for both the enumeration and measurement of size distribution of most all cell types. The instrumentation allows for user-selectable cell size settings and is applicable to a wide range of cell types. The method works best for spherical cells, and may be less accurate if cells are not spherical, such as for discoid cells or budding yeast. The method is appropriate for suspension as well as adherent cell cultures (1).2 Results may be reported as number of cells per milliliter or total number of cells per volume of cell suspension analyzed. Size distribution may be expressed in cell diameter or volume.1.2 Cells commonly used in tissue-engineered medical products (2) are analyzed routinely. Examples are chondrocytes (3), fibroblasts (4), and keratinocytes (5). Szabo et al. used the method for both pancreatic islet number and volume measurements (6). In addition, instrumentation using the electrical sensing zone technology was used for both count and size distribution analyses of porcine hepatocytes placed into hollow fiber cartridge extracorporeal liver assist systems. In this study (7), and others (6, 8), the automated electrical sensing zone method was validated for precision when compared to the conventional visual cell counting under a microscope using a hemocytometer. Currently, it is not possible to validate cell counting devices for accuracy, since there not a way to produce a reference sample that has a known number of cells. The electrical sensing zone method shall be validated each time it is implemented in a new laboratory, it is used on a new cell type, or the cell counting procedure is modified.1.3 Electrical sensing zone instrumentation (commonly referred to as a Coulter counter) is manufactured by a variety of companies and is based upon electrical impedance. This test method, for cell counting and sizing, is based on the detection and measurement of changes in electrical resistance produced by a cell, suspended in a conductive liquid, traversing through a small aperture (see Fig. 1(9)). When cells are suspended in a conductive liquid, phosphate-buffered saline for instance, they function as discrete insulators. When the cell suspension is drawn through a small cylindrical aperture, the passage of each cell changes the impedance of the electrical path between two submerged electrodes located on each side of the aperture. An electrical pulse, suitable for both counting and sizing, results from the passage of each cell through the aperture. The path through the aperture, in which the cell is detected, is known as the “electronic sensing zone.” This test method permits the selective counting of cells within narrow size distribution ranges by electronic selection of the generated pulses. While the number of pulses indicates cell count, the amplitude of the electrical pulse produced depends on the cell's volume. The baseline resistance between the electrodes is due to the resistance of the conductive liquid within the boundaries of the aperture. The presence of cells within the “electronic sensing zone” raises the resistance of the conductive pathway that depends on the volume of the cell. Analyses of the behavior of cells within the aperture demonstrates that the height of the pulse produced by the cell is the parameter that most nearly shows proportionality to the cell volume.1.4 Limitations are discussed as follows:1.4.1 Coincidence—Occasionally, more than a single cell transverses the aperture simultaneously. Only a single larger pulse, as opposed to two individual pulses, is generated. The result is a lower cell count and higher cell volume measurement. The frequency of coincidence is a statistically predictable function of cell concentration that is corrected by the instrument. This is called coincidence correction (8). This phenomenon may be reduced by using lower cell concentrations.1.4.2 Viability—Electrical sensing zone cell counting enumerates both viable and nonviable cells and cannot determine percent viable cells. A separate test, such as Trypan blue, is required to determine percent viable cells.1.4.3 Cell Diameter—This is a function of the size range capability of the aperture size selected. Measurements may be made in the cell diameter range of 0.6 μm to 1200 μm. Setting the counting size range on the instrument can affect the test results, especially if the cell size has a large distribution, and should be carefully controlled to help achieve repeatability.1.4.4 Size Range of the Aperture—The size range for a single aperture is proportional to its diameter. The response has been found to depend linearly on diameter over a range from 2 % to 80 % of the diameter. However, the aperture tube may become prone to blockage at levels greater than 60 % of diameter. Therefore, the practical operating range of the aperture is considered to be 2 % to 60 % of the diameter.1.4.5 Humidity—10 % to 85 %.1.4.6 Temperature—10 °C to 35 °C.1.4.7 Electrolyte Solution—The diluent for cell suspension shall provide conductivity and have minimal effect on cell size. The electrolyte of choice is commonly phosphate-buffered saline.

定价： 515元 / 折扣价： 438 元 加购物车

1.1 This practice provides a protocol for the assessment of the effect of materials used in the fabrication of medical devices, that will contact blood, on the morphology of white blood cells.1.2 This practice is intended to evaluate the acute in vitro effects of materials intended for use in contact with blood.1.3 This practice uses direct contact of the material with blood, and extracts of the material are not used.1.4 This practice is one of several developed for the assessment of the biocompatibility of materials. Practice F 748 provides general guidance for the selection of appropriate methods for testing materials for a specific application.1.5 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.1.6 Identification of a supplier of materials or reagents is for the convenience of the user and does not imply single source. Appropriate materials and reagents may be obtained from many commercial supply houses.

定价： 0元 / 折扣价： 0 元

5.1 The calculated error in the photovoltaic device current determined from the spectral mismatch parameter can be used to determine if a measurement will be within specified limits before the actual measurement is performed.5.2 The spectral mismatch parameter also provides a means of correcting the error in the measured device current due to spectral mismatch.5.2.1 The spectral mismatch parameter is formulated as the fractional error in the short-circuit current due to spectral and temperature differences.5.2.2 Error due to spectral mismatch is corrected by multiplying a reference cell’s measured short-circuit current by M , a technique used in Test Methods E948 and E1036.5.3 Because all spectral quantities appear in both the numerator and the denominator in the calculation of the spectral mismatch parameter (see 8.1), multiplicative calibration errors cancel, and therefore only relative quantities are needed (although absolute spectral quantities may be used if available).5.4 Temperature-dependent spectral mismatch is a more accurate method to correct photovoltaic current measurements compared with fixed-value temperature coefficients.31.1 This test method provides a procedure for the determination of a spectral mismatch parameter used in performance testing of photovoltaic devices.1.2 The spectral mismatch parameter is a measure of the error introduced in the testing of a photovoltaic device that is caused by the photovoltaic device under test and the photovoltaic reference cell having non-identical quantum efficiencies, as well as mismatch between the test light source and the reference spectral irradiance distribution to which the photovoltaic reference cell was calibrated.1.2.1 Examples of reference spectral irradiance distributions are Tables E490 or G173.1.3 The spectral mismatch parameter can be used to correct photovoltaic performance data for spectral mismatch error.1.4 Temperature-dependent quantum efficiencies are used to quantify the effects of temperature differences between test conditions and reporting conditions.1.5 This test method is intended for use with linear photovoltaic devices in which short-circuit is directly proportional to incident irradiance.1.6 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.1.7 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.1.8 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

定价： 590元 / 折扣价： 502 元 加购物车

1.1 This test method covers a procedure for the determination of a spectral mismatch parameter used in the testing of photovoltaic devices. 1.2 The spectral mismatch parameter is a measure of the error, introduced in the testing of a photovoltaic device, caused by mismatch between the spectral responses of the photovoltaic device and the photovoltaic reference cell, as well as mismatch between the test light source and the reference spectral irradiance distribution to which the photovoltaic reference cell was calibrated. Examples of reference spectral irradiance distributions are Tables E 490, E 891, or E 892. 1.3 The spectral mismatch parameter can be used to correct photovoltaic performance data for spectral mismatch error. 1.4 This test method is intended for use with linear photovoltaic devices. 1.5 There is no similar or equivalent ISO standard. 1.6 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use. 1.7 The values stated in SI units are to be regarded as the standard.

定价： 0元 / 折扣价： 0 元

4.1 This test method is useful for assessing the cytotoxic potential of new materials and formulations and as part of a quality control program for established medical devices and components.4.2 This test method assumes that assessment of cytotoxicity provides useful information to aid in predicting the potential clinical applications in humans. Cell culture methods have shown good correlation with animal assays and are frequently more sensitive to cytotoxic agents.4.3 This cell culture test method is suitable for incorporation into specifications and standards for materials to be used in the construction of medical devices that are to be implanted into the human body or placed in contact with tissue fluids or blood on a long-term basis.4.4 Some biomaterials with a history of safe clinical use in medical devices are cytotoxic. This test method does not imply that all biomaterials must pass this assay to be considered safe for clinical use (Practice F748).1.1 This test method is appropriate for materials in a variety of shapes and for materials that are not necessarily sterile. This test method would be appropriate in situations in which the amount of material is limited. For example, small devices or powders could be placed on the agar and the presence of a zone of inhibition of cell growth could be examined.1.1.1 This test method is not appropriate for leachables that do not diffuse through agar or agarose.1.1.2 While the agar layer can act as a cushion to protect the cells from the specimen, there may be materials that are sufficiently heavy to compress the agar and prevent diffusion or to cause mechanical damage to the cells. This test method would not be appropriate for these materials.1.2 The L-929 cell line was chosen because it has a significant history of use in assays of this type. This is not intended to imply that its use is preferred, only that the L-929 is an established cell line, well characterized and readily available, that has demonstrated reproducible results in several laboratories.1.3 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.1.4 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.

定价： 590元 / 折扣价： 502 元 加购物车

1.1 This practice covers the introduction of a foreign substance into mammalian body that may induce the formation of an immune response. The immune response may lead to inadvertent tissue damage and be an undesirable event. In the standard protocols for biocompatibility testing, various studies in animals are done. These animals or their blood and tissues could be used to determine if immune responses have occurred and what types have occurred. At the current time, the immunologic testing in biocompatibility protocols is very limited. Techniques can be developed in the future which are simple, reliable, and sensitive.1.2 It is the purpose of this practice to delineate some possible test methods. It must be remembered that these are protocols for use in biocompatibility testing, they are not diagnostic tests for evaluation of human conditions. Diagnostic test for use on humans must go through evaluation at the regulatory agencies. The tests described here are clearly adaptable for use in humans and can be used for research purposes and provide data in clinical trials, but are not necessarily cleared for diagnostic purposes. This practice presents selected methods. Other validated methods may be equally applicable.1.3 The values state in SI units are to be regarded as the standard.1.4 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.

定价： 0元 / 折扣价： 0 元

This specification covers preformed open-cell sponge rubber gaskets, for use in new or reconditioned pails or drums, of the following classes: Class A and Class B, each divided into Grade 1, Grade 2, and Grade 3. Cellular sponge rubber gaskets shall be made by incorporating a blowing agent into the compound, such as sodium bicarbonate, that gives off a gas which expands the mass during the vulcanization process, and shall be manufactured from natural rubber, synthetic rubber, or rubber-like materials, together with added compounding ingredients. Unless otherwise specified, gasket sponge rubber shall have a natural skin on both the top and bottom surfaces. Cellular rubber shall conform to the prescribed requirements as to physical properties such as (1) compression at deflection, (2) change in volume upon oil immersion, (3) change in compression value after heat aging, (4) compression set, and (5) color (tan or black). The following test methods shall be used: (1) compression deflection test, (2) oil immersion test, (3) heat oven aging test, and (4) compression set test under constant deflection. The formula for calculating the compression set is given. The requirements for sampling, test specimens and slabs, and measurements of test specimen such as width and thickness are detailed as well. The location from which standard test specimens are to be cut when testing standard test slabs or commercial flat sheets and the four-cavity frame for standard test slabs of cellular rubbers are illustrated.1.1 This specification covers preformed open–cell sponge rubber gaskets of the following classes for use in new or reconditioned pails or drums.1.1.1 Class A—Non–Oil Resistant.1.1.2 Class B—Oil Resistant.1.2 The values stated in SI units are to be regarded as the standard.1.3 The following safety hazards caveat pertains only to Section 10, General Test Methods. This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.NOTE 1: ISO Equivalency Statement—This proposed specification was found to be not equivalent.1.4 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

定价： 590元 / 折扣价： 502 元 加购物车

定价： 无文本 / 折扣价： 0 元